FY2029 EPS Estimates for Immunome Boosted by HC Wainwright

Immunome, Inc. (NASDAQ:IMNM) – Research analysts at HC Wainwright boosted their FY2029 earnings per share estimates for Immunome in a research report issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $0.69 per share for the year, up from their prior estimate of $0.63. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Immunome’s FY2030 earnings at $1.35 EPS.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 75.83% and a negative net margin of 1,687.08%.

A number of other analysts have also recently weighed in on IMNM. Leerink Partners set a $40.00 price objective on shares of Immunome in a report on Monday, December 15th. Wedbush reissued an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. Lake Street Capital upped their price target on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Truist Financial initiated coverage on shares of Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Thursday, January 22nd. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Immunome presently has an average rating of “Moderate Buy” and a consensus price target of $32.33.

Immunome Stock Down 2.1%

NASDAQ IMNM traded down $0.47 on Thursday, hitting $22.05. 260,603 shares of the stock were exchanged, compared to its average volume of 1,550,569. The company has a market cap of $2.43 billion, a PE ratio of -9.11 and a beta of 2.12. The company has a 50-day moving average price of $22.78 and a 200-day moving average price of $17.58. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $27.65.

Institutional Investors Weigh In On Immunome

A number of large investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its position in shares of Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after buying an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA raised its holdings in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after acquiring an additional 1,667,432 shares in the last quarter. State Street Corp raised its stake in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Immunome

In related news, Director Isaac Barchas sold 383,200 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the sale, the director owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. This represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Clay B. Siegall bought 4,729 shares of the business’s stock in a transaction dated Tuesday, December 30th. The stock was acquired at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the purchase, the chief executive officer owned 665,254 shares in the company, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 68,518 shares of company stock worth $1,453,958. 7.69% of the stock is currently owned by company insiders.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.